MicroRNA 100: A context dependent miRNA in prostate cancer

Clinics

Volumn 68, Issue 6, 2013, Pages 797-802

  Leite, Katia R M ^a   Morais, Denis R ^a   Reis, Sabrina T ^a   Viana, Nayara ^a   Moura, Caio ^a   Florez, Manuel Garcia ^a   Silva, Iran A ^a   Dip, Nelson ^a   Srougi, Miguel ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Gene expression; Micro RNA; miR 100; PCR; Prostate cancer; Protein expression; Western blot

Indexed keywords

MICRORNA; MIRN100 MICRORNA, HUMAN;

ARTICLE; DISEASE COURSE; GENE EXPRESSION REGULATION; GENE TARGETING; GENETICS; HUMAN; MALE; METABOLISM; PHYSIOLOGY; PREDICTIVE VALUE; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; HUMANS; MALE; MICRORNAS; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 84879288418     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(06)12     Document Type: Article

References (13)

1. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med. 2009;60:167-79, http://dx.doi.org/10.1146/annurev.med.59.053006.104707.
2. Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A, Dall'Oglio MF, et al. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol. 2011;185(3):1118-22, http://dx.doi.org/10.1016/j.juro.2010.10.035.
3. Leite KR, Sousa-Canavez JM, Reis ST, Tomiyama AH, Camara-Lopes LH, Sanudo A, et al. Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol. 2011;29(3):265-9, http://dx.doi.org/10.1016/j.urolonc.2009.02.002.
4. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274-93, http://dx.doi.org/10.1016/j.cell.2012.03.017.
5. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature reviews. Cancer. 2002;2(7):489-501, http://dx.doi.org/10.1038/nrc839.
6. Yoshimoto M, Ding K, Sweet JM, Ludkovski O, Trottier G, Song KS, et al. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2012.
7. Uzoh CC, Perks CM, Bahl A, Holly JM, Sugiono M, Persad RA. PTENmediated pathways and their association with treatment-resistant prostate cancer. BJU international. 2009;104(4):556-61, http://dx.doi.org/10.1111/j.1464-410X.2009.08411.x.
8. Rowbotham SP, Barki L, Neves-Costa A, Santos F, Dean W, Hawkes N, et al. Maintenance of silent chromatin through replication requires SWI/ SNF-like chromatin remodeler SMARCAD1. Mol Cell. 2011;42(3): 285-96, http://dx.doi.org/10.1016/j.molcel.2011.02.036.
9. Hisaoka M, Matsuyama A, Nagao Y, Luan L, Kuroda T, Akiyama H, et al. Identification of altered MicroRNA expression patterns in synovial sarcoma. Gene. 2011;50(3):137-45, http://dx.doi.org/10.1002/gcc.20837.
10. Zhou Y, Santoro R, Grummt I. The chromatin remodeling complex NoRC targets HDAC1 to the ribosomal gene promoter and represses RNA polymerase I transcription. EMBO J. 2002;21(17):4632-40, http://dx.doi.org/10.1093/emboj/cdf460.
11. Borre M, Hoyer M, Nerstrom B, Overgaard J. DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure. Prostate. 1998;36(4):244-9.
12. Bantis A, Gonidi M, Athanassiades P, Tsolos C, Liossi A, Aggelonidou E, et al. Prognostic value of DNA analysis of prostate adenocarcinoma: correlation to clinicopathologic predictors. J Exp Clin Cancer Res. 2005;24(2):273-8.
13. Bessiere D, Lacroix C, Campagne S, Ecochard V, Guillet V, Mourey L, et al. Structure-function analysis of the THAP zinc finger of THAP1, a large C2CH DNA-binding module linked to Rb/E2F pathways. J Biol Chem. 2008;283(7):4352-63.